Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

NCT01265823 | Completed Phase 4 Results

• 1 other identifier: W11-050
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 8

Brief Summary

W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional systemic psoriasis treatment or who are candidates for systemic therapy.

Conditions

Psoriasis

Keywords

Humira; Adalimumab; Plaque Psoriasis

Outcome Measures

Primary Outcomes (4)

• Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 4

  PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 4. The improvement in PASI score was used as a measure of efficacy.

  Week 4

• Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 16

  PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy.

  Week 16

• Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 4

  Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score \<6 indicates that psoriasis has small or no effect at all on participant's life.

  Week 4

• Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 16

  Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score \<6 indicates that psoriasis has small or no effect at all on participant's life.

  Week 16

Secondary Outcomes (18)

• Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 4

  Baseline, Week 4

• Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 16

  Baseline, Week 16

• Dermatology Life Quality Index (DLQI) Categories at Week 4

  Week 4

• Dermatology Life Quality Index (DLQI) Categories at Week 16

  Week 16

• Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 4

  Week 4

Study Arms (1)

Adalimumab

EXPERIMENTAL

Biological: Adalimumab

Interventions

Adalimumab BIOLOGICAL

Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.

Also known as: ABT-D2E7, Humira

Adalimumab

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able and willing to give written informed consent prior to any study related procedures and to comply with the requirements of the study protocol
• Male and female subjects between 18 and 75 years old
• Diagnosis of moderate to severe types I and II plaque psoriasis (Type I : symptoms onset before 40 years old; Type II: symptoms onset after 40 years old), with at least 6 months of duration
• Documented moderate to severe plaque psoriasis based on Psoriasis Area and Severity Index (PASI) score \>10
• Subjects naïve to adalimumab therapy
• Subject must be evaluated for active and latent tuberculosis (TB) infection by using a Purified Protein Derivative (PPD) skin test, chest x-ray (posterior to anterior (PA) and lateral views) and a detailed review of the subject's medical history. This screening must be negative
• A negative pregnancy test (serum human chorionic gonadotrophin) for women of childbearing potential prior to start of study treatment. (Non-childbearing potential is defined as postmenopausal for at least 1 year or surgically sterile \[bilateral tubal ligation, bilateral oophorectomy or hysterectomy\])
• Able and willing to self-administer subcutaneous injections or have available a suitable person to administer subcutaneous injections
• Subject is judged to be in generally good health as determined by the investigator

You may not qualify if:

• Prior treatment with any investigational agent within 30 days, or five half-lives of the product, which ever is longer. Subject has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or five half lives (whichever is longer) of the drug prior to study entry (Baseline Visit)
• Subject has other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with the evaluation of psoriasis or compromise the subject's safety
• Subject has a history of dysplasia, malignancy (including lymphoma and leukemia), or lymphoproliferative disease other than: a. Successfully and completely treated non-metastatic squamous or basal cell carcinoma of the skin with no recurrence within the last five years. b. Localized carcinoma in situ of the cervix or cervical dysplasia, with no recurrence within the last five years
• Persistent or recurrent infections or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days, or oral antibiotics, oral antivirals or oral antifungals within 14 days prior to Baseline Visit
• Other medical conditions: uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure New York Heart Association (NYHA) III-IV, recent stroke (within three months), chronic leg ulcer and any other condition (e.g., indwelling urinary catheter) which, in the opinion of the investigator, may place the subject at risk
• Previous diagnosis or signs highly indicative of central nervous system demyelinating diseases (e.g., optic neuritis, ataxia, apraxia)
• History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active TB
• Female subjects who are pregnant or breast-feeding
• History of clinically significant drug or alcohol abuse in the last year
• Subject started receiving a new topical therapy within the last four weeks prior to the Baseline visit for areas other than the palms, soles of feet, axilla and groin
• Subject started being treated with ultraviolet B (UVB) phototherapy, within the last four weeks prior to the Baseline visit
• Subject was treated with psoralen ultraviolet A (PUVA) phototherapy within the last four weeks prior to the Baseline visit
• Subject has been initiated on a new systemic agent within the last four weeks prior to the Baseline visit
• Patients with history of atopy
• Patients with any other autoimmune disease such as systemic lupus erythematosus (SLE) , Sdx Sjögren, vasculitis etc

Sponsors & Collaborators

• AbbVie (prior sponsor, Abbott): lead

Study Sites (8)

Site Reference ID/Investigator# 50942

Circuito Comercial Satelite, Mexico

Location

Site Reference ID/Investigator# 40964

Iztapalapa, 04230, Mexico

Location

Site Reference ID/Investigator# 50943

Mexico City, 06780, Mexico

Location

Site Reference ID/Investigator# 40965

Monterrey, 64460, Mexico

Location

Site Reference ID/Investigator# 40962

Monterrey, 64718, Mexico

Location

Site Reference ID/Investigator# 40662

Toluca, 50120, Mexico

Location

Site Reference ID/Investigator# 41062

Toluca, 50120, Mexico

Location

Site Reference ID/Investigator# 40963

Zapopan, 45190, Mexico

Location

Related Links

• Related info

MeSH Terms

Conditions

Psoriasis

Interventions

Adalimumab

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Results Point of Contact

• Title: Global Medical Services
• Organization: AbbVie (prior sponsor, Abbott)

800-633-9110

Study Officials

• Jose-Luis Canadas, Medical Director, MD

  AbbVie

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 22, 2010
• First Posted: December 23, 2010
• Study Start: October 1, 2010
• Primary Completion: February 1, 2012
• Study Completion: February 1, 2012
• Last Updated: March 11, 2013
• Results First Posted: March 11, 2013

Record last verified: 2013-02

Locations

ME (8)